Suppr超能文献

瑞马唑仑与传统镇静剂用于镇静:疗效和安全性结局的系统评价和荟萃分析。

Remimazolam versus traditional sedatives for procedural sedation: a systematic review and meta-analysis of efficacy and safety outcomes.

机构信息

Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China -

出版信息

Minerva Anestesiol. 2022 Nov;88(11):939-949. doi: 10.23736/S0375-9393.22.16631-9. Epub 2022 Jul 5.

Abstract

INTRODUCTION

Remimazolam is a novel and ultra-short-acting benzodiazepine currently approved for procedural sedation and induction of general anaesthesia, with a possible indication for ICU sedation. This study aimed to evaluate the efficacy and safety of remimazolam and traditional sedatives for patients undergoing procedural sedation.

EVIDENCE ACQUISITION

We systematically searched Cochrane Library, Embase, PubMed, Web of Science and ClinicalTrials.gov for randomized controlled trials of procedural sedation performed with remimazolam versus traditional sedatives. Data from the eligible studies were combined to calculate pooled risk ratio or standardized mean difference.

EVIDENCE SYNTHESIS

Eleven studies of 2356 patients met the inclusion criteria. The results showed that remimazolam was associated with a higher procedure success rate (RR: 1.28, 95% CI: 1.07 to 1.52, P=0.006; I=99%), a shorter duration of recovery after procedure (SMD: -0.56, 95% CI: -0.98, -0.14, P=0.009; I=89%), and an earlier patient discharge after procedure (SMD: -0.37, 95% CI: -0.49, -0.25, P<0.00001; I=0%) in comparison with traditional sedatives. There were no statistically significant differences in onset time, procedure time, and cognitive recovery between remimazolam and traditional sedatives groups. Remimazolam significantly decreased the rate of bradycardia (RR: 0.65, 95% CI: 0.43, 0.97, P=0.04; I=0%), hypotension (RR: 0.57, 95% CI: 0.40, 0.80, P=0.001; I=80%), and respiratory depression/hypoxia (RR: 0.46, 95% CI: 0.25, 0.83, P=0.01; I=61%) compared to traditional sedatives.

CONCLUSIONS

Remimazolam is a safe and effective sedative for procedural sedation on account of a higher success procedure rate, a faster recovery, a shorter discharge time, and a superior safety profile in comparison with traditional sedatives. Larger sample-sized and well-designed clinical trials are needed to verify our finding.

摘要

介绍

雷米唑仑是一种新型的超短效苯二氮䓬类药物,目前已获准用于程序镇静和全身麻醉的诱导,可能适用于 ICU 镇静。本研究旨在评估雷米唑仑与传统镇静剂在接受程序镇静的患者中的疗效和安全性。

证据获取

我们系统地检索了 Cochrane 图书馆、Embase、PubMed、Web of Science 和 ClinicalTrials.gov,以获取雷米唑仑与传统镇静剂进行程序镇静的随机对照试验。将合格研究的数据合并以计算汇总风险比或标准化均数差。

证据综合

符合纳入标准的 11 项研究共纳入 2356 例患者。结果表明,与传统镇静剂相比,雷米唑仑与更高的手术成功率相关(RR:1.28,95%CI:1.07-1.52,P=0.006;I=99%),术后恢复时间更短(SMD:-0.56,95%CI:-0.98,-0.14,P=0.009;I=89%),术后患者出院更早(SMD:-0.37,95%CI:-0.49,-0.25,P<0.00001;I=0%)。雷米唑仑与传统镇静剂组之间的起效时间、手术时间和认知恢复无统计学差异。雷米唑仑显著降低心动过缓发生率(RR:0.65,95%CI:0.43-0.97,P=0.04;I=0%)、低血压发生率(RR:0.57,95%CI:0.40-0.80,P=0.001;I=80%)和呼吸抑制/缺氧发生率(RR:0.46,95%CI:0.25-0.83,P=0.01;I=61%)。

结论

与传统镇静剂相比,雷米唑仑作为一种安全有效的镇静剂,在程序镇静中具有更高的成功率、更快的恢复、更短的出院时间和更好的安全性。需要更大样本量和精心设计的临床试验来验证我们的发现。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验